Vanessa Vanstee, MD
Allergy & Immunology · Westfield, MANPI 1528094372
Payments from drug & device makers
Across 706 payments — averaging $26.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- AstraZeneca$3K
- Pfizer$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$783
- plus $5K from 24 others
What the payments were for
- Consulting fees$4,12522%
- Travel & lodging$1,4968%
- Food & beverage$12,80469%
- Education$2131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 117 | $6,788 |
| AstraZeneca | 129 | $2,769 |
| Pfizer | 72 | $1,406 |
| GSK | 63 | $1,062 |
| Regeneron Healthcare Solutions, Inc. | 40 | $1,002 |
| Sanofi | 39 | $783 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $643 |
| CSL Behring | 29 | $608 |
| Pharming Healthcare, Inc. | 29 | $607 |
| Amgen(2 entities) | 25 | $505 |
| Boehringer Ingelheim | 27 | $465 |
| AbbVie(2 entities) | 14 | $371 |
| Biocryst US Sales Co., LLC | 23 | $216 |
| Teva Pharmaceuticals USA, Inc. | 15 | $216 |
| Grifols USA, LLC | 9 | $190 |
| Lilly USA, LLC | 5 | $141 |
| GC Biopharma USA, Inc. | 6 | $134 |
| Octapharma USA, Inc. | 6 | $132 |
| LEO Pharma Inc. | 5 | $129 |
| Alk-abello, Inc | 6 | $90 |
| Kaleo, Inc. | 3 | $66 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Blueprint Medicines Corporation | 3 | $63 |
| Organon | 2 | $53 |
| Genentech USA, Inc. | 2 | $36 |
| Optinose US, Inc. | 2 | $28 |
| Covis Pharma GmbH | 2 | $23 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$125
How this compares
$18,638 in reported general payments places this provider in the 65th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 13 | $1,090,808 |
| XolairOmalizumab | 153 | $445,759 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 52 | $216,933 |
| Dupixent SyringeDupilumab | 29 | $115,604 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 28 | $83,147 |
| FasenraBenralizumab | 11 | $62,939 |
| TezspireTezepelumab-Ekko | 13 | $61,631 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $52,729 |
| NucalaMepolizumab | 12 | $45,647 |
| Advair HfaFluticasone Propion/Salmeterol | 93 | $34,981 |
| XembifyImmune Globulin,gamma(Igg)klhw | 15 | $32,221 |
| Epinephrine | 118 | $26,029 |
| Spiriva RespimatTiotropium Bromide | 29 | $23,103 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $13,448 |
| Cromolyn Sodium | 50 | $10,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $608 | $1,090,80813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $643 | $216,93352 claims |
| AstraZenecaFasenra, Tezspire, Symbicort | $2,769 | $132,45061 claims |
| GSKBreo Ellipta, Nucala, Incruse Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,062 | $130,271184 claims |
| Grifols USA, LLCGamunex-C, Xembify | $190 | $115,36843 claims |
| Boehringer IngelheimSpiriva Respimat | $465 | $23,10329 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $216 | $4,97817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Westfield
- S David MillerNorth Dartmouth$8.7M
- Wanda PhipatanakulBoston$3.2M
- Maria CastellsGardner$2.8M
- Rima RachidBoston$1.1M
- Duane WesemannBoston$1M
- Matthew GiannettiBoston$720K
- John LeeBoston$695K
- Aleena BanerjiBoston$586K
- Michael PistinerBoston$468K
- Kathleen BuchheitBoston$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.